Japanese biotech startup RevolKa Ltd. has raised ¥210 million (US$1.4 million) in a Series A extension round to further its AI-driven drug discovery platform, aiProtein®. The funding will accelerate therapeutic programs for rare diseases and expand strategic collaborations.
Source: Revolka
